Overview

STATEMENT OF NEED

Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States. An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma (RCC), which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Due to its often asymptomatic presentation, many patients have advanced disease at diagnosis, which is associated with poor outcomes. The 5-year survival rate for patients with regional RCC is only 70% and drops to a dismal 12% for those with distant metastases.

TARGET AUDIENCE

Oncology and urology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with RCC.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Distinguish the mechanisms of action of immuno-oncology agents and VEGFR TKIs in advanced RCC
• Differentiate the efficacy and safety profiles of immuno-oncology and VEGFR TKI therapies for advanced RCC
• Assess strategies to improve treatment tolerability, control adverse events, and ensure the provision of patient-centered RCC care

Learning objectives apply to all professions in the target audience. There are no prerequisites for this activity.

FACULTY

Laura S. Wood, RN, MSN, OCN® (Chairperson)
Renal Cancer Research Coordinator
Cleveland Clinic Taussig Cancer Center

Nazy Zomorodian, RNC, MSN, CUNP, CCRC
Urology Nurse Practitioner
UCLA Medical Center

Virginia Seery, MSN, RN, ANP-BC, AOCNP®
Nurse Practitioner
Beth Israel Deaconess Medical Center

Colleen Lewis, NP
Director of Clinical Operations, Phase I Clinical Trials Program
Winship Cancer Institute

REGISTRATION

There is no fee to participate in or claim NCPD credit for this activity.

Provided by

Nursing Continuing Professional Development

i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.6 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.

ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN^®, CPHON^®, CBCN^®, AOCNP^®, AOCNS^®, and BMTCN^® renewal candidates may apply 1 ILNA point toward:

• Care Continuum
• Coordination of Care
• Diagnosis and Staging
• Oncology Nursing Practice
• Palliative Care
• Scientific Basis for Practice
• Symptom Management
• Treatment

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS

i3 Health endorses the standards of the ANCC that require everyone in a position to control the content of a NCPD activity to disclose all financial relationships with commercial interests that are related to the content of the NCPD activity. NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and commercial interests:

Laura S. Wood, RN, MSN, OCN^® discloses that she has served on the speakers' bureau for Bristol Myers Squibb and Merck. She has also served as a consultant for Eisai.

The i3 Health planners and managers have nothing to disclose.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This educational activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by independent educational grants from Eisai and Merck.

Aggregate participant data will be shared with commercial supporters of this activity.

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc.). Please contact i3 Health prior to the live event at 973-928-8085 or This email address is being protected from spambots. You need JavaScript enabled to view it..

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at This email address is being protected from spambots. You need JavaScript enabled to view it.